DNA Extraction Systems (Maxwell RSC 48 or Equal)

This is a combined for commercial products prepared in accordance with the format prescribed in FAR 12.202, Streamlined Procedures for Evaluation and Solicitation for Commercial Products and Commercial Services, as supplemented with the additional information included in this notice. This announcement constitutes the only solicitation. Quotations are being requested, and a separate written solicitation will not be issued. Solicitation Number HFP-2026-133524 is issued as a Request for Quotations (RFQ) for the acquisition of Maxwell RSC 48 DNA Extraction Systems or Equal, including delivery, installation, on-site training, warranty support, and related services for FDA laboratory facilities. This acquisition is not set aside for small business concerns. It is being conducted using full and open competition. The solicitation incorporates provisions and clauses by reference. The full text of incorporated provisions and clauses is available at https://www.acquisition.gov. This acquisition is not rated under the Defense Priorities and Allocations System (DPAS). Line Items CLIN Unit 0001 Maxwell RSC 48 DNA Extraction System or Equal Each 0002 Installation Services Each 0003 On-Site Training Each 0004 One-Year Warranty Support Each Requirement The contractor shall furnish all labor, materials, equipment, transportation, supervision, installation, training, warranty support, and incidental services necessary to provide Maxwell RSC 48 DNA Extraction Systems or Equal in accordance with the salient characteristics and performance

requirements contained in the attached solicitation. Equal products shall meet or exceed all required physical, functional, operational, and performance characteristics identified in the solicitation. Offerors proposing an equal product shall submit sufficient technical documentation to demonstrate compliance. Delivery and Acceptance Delivery shall be completed within 90 calendar days after receipt of order. Installation shall be completed within 14 calendar days after delivery. FOB: Destination. Inspection and acceptance shall occur at destination after successful delivery, installation, operational testing, and completion of required training. Initial delivery locations include FDA laboratory facilities located in Arkansas, Georgia, California, Colorado, Washington, and New York. Solicitation Provisions The following solicitation provisions apply to this acquisition: FAR 52.212-1,

Instructions to Offerors—Commercial Products and Commercial Services, with Addendum FAR 52.212-2, Evaluation—Commercial Products and Commercial Services FAR 52.252-1, Solicitation Provisions Incorporated by Reference All additional provisions identified in the attached solicitation Contract Clauses The resulting BPA will incorporate the clauses identified in the attached solicitation, including: FAR 52.212-4, Contract Terms and Conditions—Commercial Products and Commercial Services, with Addenda FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders—Commercial Products and Commercial Services Applicable HHSAR clauses Additional contract

requirements contained in the solicitation, including installation, training, warranty, invoicing, and electronic payment

requirements. Evaluation Award will be made using the Lowest Price Technically Acceptable (LPTA) source selection process. Evaluation factors are: Technical Acceptability Past Performance Price Submission Instructions

Questions are due July 24, 2026, at 10:00 a.m. Eastern Time. Quotations are due July 31, 2026, at 10:00 a.m. Eastern Time. Electronic quotations shall be submitted to the